Introduction {#tca13197-sec-0001}
============

Recent clinical trials demonstrated that PD‐1 blockade showed high clinical efficacy in patients with non‐small cell lung cancer (NSCLC) who had a high PD‐L1 tumor proportion score.[1](#tca13197-bib-0001){ref-type="ref"}, [2](#tca13197-bib-0002){ref-type="ref"}, [3](#tca13197-bib-0003){ref-type="ref"}, [4](#tca13197-bib-0004){ref-type="ref"} Clinical trials generally exclude patients with renal dysfunction who are receiving hemodialysis (HD), and it is therefore unclear whether these patients can be safely and effectively treated with anti‐PD‐1 therapy.

In this article we describe a NSCLC patient on HD who was treated with pembrolizumab. An obvious clinical response was obtained after only one treatment. The therapeutic effect was maintained and no recurrence had occurred at 50 weeks after discontinuation of treatment.

We have previously developed and reported a method to monitor binding of the anti‐PD‐1 antibody nivolumab to T cells in NSCLC patients.[5](#tca13197-bib-0005){ref-type="ref"} The same method could be used to detect pembrolizumab since both anti‐PD‐1 antibodies comprise fully humanized IgG4 and interfere with recognition by the PD‐1‐detecting antibody EH12.1.[6](#tca13197-bib-0006){ref-type="ref"}, [7](#tca13197-bib-0007){ref-type="ref"} In this study, we monitored pembrolizumab binding to peripheral blood T cells in a patient on HD, and found that the immunokinetics of pembrolizumab were similar to those in control patients with normal renal function.

Case report {#tca13197-sec-0002}
===========

A 72‐year‐old male patient was diagnosed with stage IIIB lung adenocarcinoma harboring neither *EGFR* mutation nor *ALK* rearrangement. Positron emission tomography (PET) showed a primary lesion in the right lower lobe and metastases to multiple lymph nodes, including the right supraclavicular lymph node (Fig [1](#tca13197-fig-0001){ref-type="fig"}). Although this patient was ineligible for cytotoxic chemotherapy due to anemia and HD,[8](#tca13197-bib-0008){ref-type="ref"} and could not undergo radiotherapy due to the large irradiated area in the lung, he was eligible to receive anti‐tumor treatment. PD‐L1 evaluation was performed by immunohistochemistry using the 22C3 antibody, and a biopsy sample showed a PD‐L1 tumor proportion score of 80%. Based on this clinical background, intravenous pembrolizumab 200 mg was administered as first‐line therapy. Three weeks after the first injection, he developed mild ileus and aspiration pneumonia which resolved with conservative treatment. The treatment was discontinued because immune‐related adverse events[9](#tca13197-bib-0009){ref-type="ref"} could not completely be ruled out as a cause of his condition. Despite the fact that the patient received only a single dose of pembrolizumab, his clinical response was maintained and follow‐up positron emission tomography/computed tomography revealed complete metabolic remission[10](#tca13197-bib-0010){ref-type="ref"} at 50 weeks after the dose (Fig [1](#tca13197-fig-0001){ref-type="fig"}). During his clinical course, peripheral blood was analyzed at three time points: at pretreatment, eight and 24 weeks after the injection. We previously developed a method to monitor nivolumab binding to T cells after discontinuation of treatment.[5](#tca13197-bib-0005){ref-type="ref"} This method was available for monitoring pembrolizumab binding in this patient. Briefly, we prepared two types of antibodies for the analysis: the first, EH12.1, binds to PD‐1 expressed on T cells, and the second, HP6025, is an anti‐IgG4 antibody identifying the PD‐1‐blocking antibodies consisted of humanized IgG4, nivolumab and pembrolizumab. EH12.1 recognizes a similar epitope as nivolumab and pembrolizumab. After treatment, EH12.1 does not detect PD‐1 expressed on T cells if PD‐1 is completely blocked by therapeutic antibodies, whereas HP6025 detects nivolumab and pembrolizumab is bound to T cells. This method simply identified the status of pembrolizumab binding to T cells in this patient. The binding status was classified as complete binding (CB), partial binding (PB), or no binding (NB).[5](#tca13197-bib-0005){ref-type="ref"} In this patient, T cells at eight and 24 weeks after injection showed CB and NB, respectively (Fig [2](#tca13197-fig-0002){ref-type="fig"}). We compared the immunokinetics of pembrolizumab binding in the current patient with that in a control group consisting of five lung adenocarcinoma patients with normal renal function who were treated with one to four doses of pembrolizumab (Fig [3](#tca13197-fig-0003){ref-type="fig"}a). Follow‐up in controls was performed between nine and 25 weeks after pembrolizumab discontinuation. One representative control patient showed decreased CB (red) and an absolute loss of CB at 25 weeks after the final dose (Fig [3](#tca13197-fig-0003){ref-type="fig"}b). The other four patients showed a similar trend in decreased CB, with an absolute CB loss at around 20--25 weeks (Fig [3](#tca13197-fig-0003){ref-type="fig"}c).

![Axial computed tomography (CT) (upper lane) and positron emission tomography/CT images (lower lane) at indicated time points.](TCA-10-2183-g001){#tca13197-fig-0001}

![Staining of PD‐1 and IgG4 in blood CD8 and CD4 T cells from the patient on hemodialysis. Flow cytometry analysis was performed at pretreatment (pre) and at eight weeks and 24 weeks after discontinuation of pembrolizumab. CB, complete binding (red); NB, no binding (green); PB, partial binding (blue).](TCA-10-2183-g002){#tca13197-fig-0002}

![(**a**) Characteristics of control lung adenocarcinoma patients with normal renal function. (**b**) Representative staining results examining time‐dependent changes in pembrolizumab binding to T cells after drug discontinuation. Flow cytometry analysis was performed to evaluate PD‐1 and IgG4 staining in blood CD8 and CD4 T cells from patient 1 (Pt. 1). (**c**) The percent of complete binding of pembrolizumab in CD8 and CD4 T cells was followed up in five NSCLC patients (\*follow‐up discontinued due to hospital change or death). (![](TCA-10-2183-g004.jpg "image")) CD8 T cells and (![](TCA-10-2183-g005.jpg "image")) CD4 T cells.](TCA-10-2183-g003){#tca13197-fig-0003}

Discussion {#tca13197-sec-0003}
==========

Few case reports have reported the successful administration of anti‐PD‐1 antibodies in cancer patients receiving HD.[11](#tca13197-bib-0011){ref-type="ref"}, [12](#tca13197-bib-0012){ref-type="ref"}, [13](#tca13197-bib-0013){ref-type="ref"} Here, we present a patient on HD who achieved complete remission after one dose of the anti‐PD‐1 antibody pembrolizumab, without severe adverse events. Renal impairment reportedly has little effect on the pharmacokinetics of pembrolizumab.[14](#tca13197-bib-0014){ref-type="ref"} However, no studies have visualized anti‐PD‐1 antibody binding to T cells after anti‐PD‐1 antibody discontinuation in patients on HD. Monitoring of antibody binding to T cells in the patient in this case revealed that CB was maintained at eight weeks and binding was completely lost at 24 weeks after a single pembrolizumab injection. Similar immunokinetics were confirmed in control patients treated with a small number of pembrolizumab doses, suggesting that HD had little effect on pembrolizumab metabolism, though the time points of sample collection could not be standardized among individuals. Importantly, clinical efficacy in this case was maintained independently of pembrolizumab binding at ≥24 weeks after one dose,[15](#tca13197-bib-0015){ref-type="ref"} suggesting that either T cell immune surveillance began to function efficiently after treatment or viable cancer cells were cleared before pembrolizumab binding was lost.

Pembrolizumab may be a vital treatment option for lung cancer patients on HD who have no contraindications. Moreover, our monitoring strategy for anti‐PD‐1 antibody binding in patients on HD could be useful for understanding the metabolism of anti‐PD‐1 antibodies and the maintenance of anti‐tumor T cell immunity after complete loss of antibody binding.
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